Celularity Inc, , Florham, New Jersey based regenerative medicine company has named Naveen Jain, founder and chief executive officer of Viome Life Sciences Inc., to its Board of Directors.
The appointment introduces a consumer-focused perspective to the regenerative medicine and biotechnology company as it pursues therapies derived from the postpartum placenta.
Jain brings a history of launching enterprises centered around emerging technologies and world-scale challenges, having previously founded InfoSpace, Intelius, TalentWise, and Moon Express. At Viome, his work utilizes artificial intelligence and molecular data to advance personalized health and nutrition.
Robert J. Hariri, chairman and chief executive officer of Celularity, emphasized that Jain’s entrepreneurial track record will be valuable as the company works to scale the commercial reach of its products and explore broader opportunities at the intersection of regenerative medicine and longevity.
Read: 17 Indian Americans in Forbes 2026 America’s Top Lawyers list (September 18, 2026)
Hariri noted that Jain shares the organization’s belief in the potential of regenerative longevity to address fundamental mechanisms of aging and age-related disease.
The addition of Jain comes at a time when healthcare is increasingly shifting from reactive treatment after symptoms appear toward proactive approaches to health.
Jain stated that he aims to help translate the potential of regenerative medicine into real-world impact, bringing commercial discipline, strategic partnerships, and a consumer-centric viewpoint to the table.
Philip A. Barach, a fellow Celularity board member, noted that Jain’s appointment arrives as the company builds upon recent progress in strengthening its capital structure and operating profile.
Read: Indian American South Dakota professor earns two professional honors (September 28, 2026)
Barach emphasized that the primary opportunity now is pairing financial discipline with an ambitious commercial vision for the assets the enterprise has already developed.
Jain joins a newly reconstituted board that currently includes Hariri, Peter H. Diamandis, and Barach, who recently joined as part of the company’s broader recapitalization and strategic repositioning.
Celularity expects to announce a fifth member to the board shortly. According to the company, Jain’s formal appointment will become effective following the completion of the applicable Rule 14f-1 information statement process.